Literature DB >> 1676988

c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material.

S Jain1, M I Filipe, W J Gullick, J Linehan, R W Morris.   

Abstract

The c-erbB-2 proto-oncogene encodes a growth factor receptor which is over-expressed in a variety of human adenocarcinomas. Recent reports suggest that it may be of value in arriving at prognosis in breast and ovarian cancer. In this study, c-erbB-2 expression was investigated in 93 routinely processed cases of gastric carcinoma, using an immunohistochemical technique. c-erbB-2 membrane immunoreactivity was observed in 11% (10/93) of tumours, all of which were of the well differentiated intestinal type (p less than 0.01). Overall, patients with tumours expressing this proto-oncogene had a significantly improved prognosis (p less than 0.05). Within the group of intestinal-type tumours, those that were c-erbB-2-positive formed a distinct sub-population which had a better prognosis (p less than 0.02), suggesting possible differences in aetiology.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676988     DOI: 10.1002/ijc.2910480506

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.

Authors:  Dong Il Park; Mun Su Kang; Suk Joong Oh; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Won Kon Han; Hungdai Kim; Seung Ho Ryu; Antonia R Sepulveda
Journal:  Int J Colorectal Dis       Date:  2006-09-01       Impact factor: 2.571

2.  Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.

Authors:  Nozomu Fuse; Yasutoshi Kuboki; Takeshi Kuwata; Tomohiro Nishina; Shigenori Kadowaki; Eiji Shinozaki; Nozomu Machida; Satoshi Yuki; Akira Ooki; Shinya Kajiura; Tetsuo Kimura; Takeharu Yamanaka; Kohei Shitara; Akiko Kawano Nagatsuma; Takayuki Yoshino; Atsushi Ochiai; Atsushi Ohtsu
Journal:  Gastric Cancer       Date:  2015-02-15       Impact factor: 7.370

3.  Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer.

Authors:  Byung Woog Kang; Dakeun Lee; Ho Young Chung; Jae Ho Han; Young-Bae Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-05       Impact factor: 4.553

Review 4.  Multimodality treatment of potentially curative gastric cancer: geographical variations and future prospects.

Authors:  Neil D Merrett
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 5.  Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.

Authors:  Jan Trøst Jørgensen
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

6.  Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization.

Authors:  T Ishikawa; M Kobayashi; M Mai; T Suzuki; A Ooi
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

7.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

Review 8.  Pathologic prognostic factors for gastrointestinal cancer.

Authors:  T Ismail; M T Hallissey; J W Fielding
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 9.  Targeted therapies in gastric cancer and future perspectives.

Authors:  Ozan Yazici; M Ali Nahit Sendur; Nuriye Ozdemir; Sercan Aksoy
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

10.  Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations.

Authors:  J F Fléjou; F Paraf; F Muzeau; F Fékété; D Hénin; S Jothy; F Potet
Journal:  J Clin Pathol       Date:  1994-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.